Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Cancer. 2016 Aug 1;122(23):3650–3656. doi: 10.1002/cncr.30231

Table 2.

Inverse probability of treatment weighted analysis for responses and survival outcomes

HCVAD + ponatinib vs. HCVAD + dasatinib HR 95% CI P
Negative MRD on D21 by FCM 0.516 0.281-0.947 0.03
Complete cytogenetic response at CR 0.238 0.078-0.722 0.01
Molecular response at CR
    CMR 0.634 0.278-1.449 0.28
    MMR or deeper 0.409 0.175-0.954 0.04
Molecular response at 3 months
    CMR 0.352 0.137-0.904 0.03
    MMR or deeper 0.195 0.044-0.854 0.03
Survival outcomes
    EFS 0.486 0.303-0.778 0.003
    OS 0.374 0.208-0.673 0.001

Abbreviations: HCVAD, hyper-CVAD; HR hazard ratio; CI, confidence interval; MRD, minimal residual disease; FCM, flow cytometry; D21, day 21 of induction therapy; CR, complete response; CMR, complete molecular response; MMR, major molecular response; EFS, event-free survival; OS, overall survival.